Home › Companies › PROTAGONIST THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and PROTAGONIST THERAPEUTICS INC.’s Form 8-K, filed June 26, 2025 (Item 5.07 on EDGAR). Page generated November 7, 2026.
Meeting of June 20, 2025: 4 items on PROTAGONIST THERAPEUTICS INC.’s Form 8-K, filed June 26, 2025: 2 approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore PROTAGONIST THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are PROTAGONIST THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 26, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Harold E. Selick, Ph.D. | 44,822,907 | -- | -- | 9,210,036 | 1,918,517 | 83% | Not verified | — |
| Elect Director: Bryan Giraudo | 42,499,790 | -- | -- | 11,533,153 | 1,918,517 | 79% | Not verified | — |
| 2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers | 50,844,517 | 2,850,473 | 337,953 | -- | 1,918,517 | 95% | Approved | — |
| 3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025 | 55,480,739 | 74,233 | 396,488 | -- | -- | 99.8% | Approved | — |
Source: PROTAGONIST THERAPEUTICS INC., Form 8-K, filed with the SEC on June 26, 2025 — read the filing on EDGAR.
Each item below shows how the 303 asset managers that disclosed a PROTAGONIST THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: To elect the Class III director nominees named below to hold office until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Harold E. Selick, Ph.D.
PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Harold E. Selick, Ph.D.”): 44,822,907 for, 9,210,036 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 89 asset managers below reported 15,056,041 for, 1,967,828 withheld, 672,052 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,414,634 | 0 | 418,662 | 0 | Mixed |
| Vanguard | 4,184,945 | 0 | 12 | 2,864 | For |
| Fidelity | 1,813,575 | 0 | 0 | 0 | For |
| State Street | 1,361,689 | 0 | 0 | 1,813 | For |
| T. Rowe Price | 923,420 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 655,557 | Withhold |
| Charles Schwab | 506,757 | 0 | 0 | 0 | For |
| Invesco | 392,327 | 0 | 0 | 0 | For |
| JPMorgan | 266,845 | 0 | 0 | 0 | For |
| Hartford | 195,842 | 0 | 0 | 0 | For |
| Equitable | 107,599 | 0 | 0 | 64,980 | Mixed |
| TIAA | 0 | 0 | 0 | 146,001 | Withhold |
| Victory Capital | 0 | 0 | 0 | 132,533 | Withhold |
| Columbia Threadneedle | 126,420 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 111,012 | Withhold |
| Lincoln Financial | 65,839 | 0 | 0 | 41,637 | Mixed |
| Jackson National | 0 | 0 | 104,036 | 0 | Abstain |
| John Hancock | 49,699 | 0 | 44,322 | 0 | Mixed |
| Northwestern Mutual | 89,634 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,963 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 84,000 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 0 | 0 | 81,994 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 0 | 66,306 | Withhold |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 65,647 | Withhold |
| Voya | 62,413 | 0 | 0 | 0 | For |
Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.
Combines 6 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: To elect the Class III director nominees named below to hold office until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Bryan Giraudo
PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Bryan Giraudo”): 42,499,790 for, 11,533,153 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 88 asset managers below reported 13,751,661 for, 3,198,245 withheld, 662,015 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,414,634 | 0 | 418,662 | 0 | Mixed |
| Vanguard | 4,184,943 | 0 | 14 | 2,864 | For |
| Fidelity | 1,813,575 | 0 | 0 | 0 | For |
| State Street | 1,361,689 | 0 | 0 | 1,813 | For |
| T. Rowe Price | 923,420 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 655,557 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 506,757 | Withhold |
| Invesco | 0 | 0 | 0 | 392,327 | Withhold |
| JPMorgan | 266,845 | 0 | 0 | 0 | For |
| Hartford | 195,842 | 0 | 0 | 0 | For |
| Equitable | 107,599 | 0 | 0 | 64,980 | Mixed |
| TIAA | 0 | 0 | 0 | 146,001 | Withhold |
| Victory Capital | 0 | 0 | 0 | 132,533 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 126,420 | Withhold |
| First Trust | 0 | 0 | 0 | 111,012 | Withhold |
| Lincoln Financial | 65,839 | 0 | 0 | 41,637 | Mixed |
| Jackson National | 0 | 0 | 104,036 | 0 | Abstain |
| John Hancock | 49,699 | 0 | 44,322 | 0 | Mixed |
| Northwestern Mutual | 68,885 | 0 | 0 | 20,749 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 85,963 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 0 | 0 | 81,994 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 0 | 66,306 | Withhold |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 65,647 | Withhold |
| Voya | 0 | 0 | 0 | 62,413 | Withhold |
| Principal | 529 | 0 | 0 | 57,887 | Withhold |
Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.
Combines 7 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers”): 50,844,517 for, 2,850,473 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,833,296 | 0 | 0 | 0 | For |
| Vanguard | 4,184,955 | 2,866 | 0 | 0 | For |
| Fidelity | 1,813,575 | 0 | 0 | 0 | For |
| State Street | 1,362,829 | 673 | 0 | 0 | For |
| T. Rowe Price | 923,420 | 0 | 0 | 0 | For |
| American Century | 0 | 655,557 | 0 | 0 | Against |
| Charles Schwab | 506,757 | 0 | 0 | 0 | For |
| Invesco | 0 | 392,327 | 0 | 0 | Against |
| JPMorgan | 266,845 | 0 | 0 | 0 | For |
| Hartford | 195,842 | 0 | 0 | 0 | For |
| Equitable | 172,579 | 0 | 0 | 0 | For |
| TIAA | 146,001 | 0 | 0 | 0 | For |
| Victory Capital | 132,533 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 126,420 | 0 | 0 | 0 | For |
| First Trust | 111,012 | 0 | 0 | 0 | For |
| Lincoln Financial | 97,609 | 9,867 | 0 | 0 | Mixed |
| Jackson National | 104,036 | 0 | 0 | 0 | For |
| John Hancock | 94,021 | 0 | 0 | 0 | For |
| Northwestern Mutual | 89,634 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,963 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 0 | 84,000 | 0 | 0 | Against |
| CARILLON SERIES TRUST | 81,994 | 0 | 0 | 0 | For |
| BNY Mellon | 66,306 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 65,647 | 0 | 0 | 0 | For |
| Voya | 62,413 | 0 | 0 | 0 | For |
Fund voting reports, all 89 managers: 16,490,374 for, 1,199,217 against, 6,330 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 5,685,801 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 4,690,516 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 3,250,000 | 0 | 0 | 0 | For |
| BVF INC/IL | 2,575,015 | 0 | 0 | 0 | For |
| State Street | 2,512,640 | 17,235 | 0 | 0 | For |
| BlackRock | 1,952,821 | 22,891 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,427,914 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,190,609 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,120,164 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 843,380 | 0 | 0 | 0 | For |
| Wellington | 772,201 | 0 | 0 | 0 | For |
| Lynx1 Capital Management LP | 733,014 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 669,798 | 0 | 0 | 0 | For |
| American Century | 0 | 668,104 | 0 | 0 | Against |
| Charles Schwab | 564,161 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 547,562 | 0 | 0 | 0 | For |
| Northern Trust | 538,911 | 526 | 0 | 0 | For |
| Invesco | 0 | 538,745 | 0 | 0 | Against |
| Fidelity | 530,649 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 508,131 | 0 | 0 | 0 | For |
| Woodline Partners LP | 480,634 | 0 | 0 | 0 | For |
| JPMorgan | 445,933 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 354,697 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 351,090 | 0 | 0 | 0 | For |
| Focus Partners Wealth | 327,499 | 8 | 0 | 0 | For |
Institutional-manager reports, all 239 managers: 36,678,330 for, 2,466,760 against, 327,521 abstained, 3,464 not voted. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025.
PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025”): 55,480,739 for, 74,233 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 90 asset managers below reported 17,651,643 for, 40,199 against, 6,330 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,833,296 | 0 | 0 | 0 | For |
| Vanguard | 4,187,821 | 0 | 0 | 0 | For |
| Fidelity | 1,813,575 | 0 | 0 | 0 | For |
| State Street | 1,363,502 | 0 | 0 | 0 | For |
| T. Rowe Price | 923,420 | 0 | 0 | 0 | For |
| American Century | 655,557 | 0 | 0 | 0 | For |
| Charles Schwab | 506,757 | 0 | 0 | 0 | For |
| Invesco | 392,327 | 0 | 0 | 0 | For |
| JPMorgan | 266,845 | 0 | 0 | 0 | For |
| Hartford | 195,842 | 0 | 0 | 0 | For |
| Equitable | 172,579 | 0 | 0 | 0 | For |
| TIAA | 146,001 | 0 | 0 | 0 | For |
| Victory Capital | 132,533 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 126,420 | 0 | 0 | 0 | For |
| First Trust | 111,012 | 0 | 0 | 0 | For |
| Lincoln Financial | 107,476 | 0 | 0 | 0 | For |
| Jackson National | 104,036 | 0 | 0 | 0 | For |
| John Hancock | 94,021 | 0 | 0 | 0 | For |
| Northwestern Mutual | 89,634 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,963 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 84,000 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 81,994 | 0 | 0 | 0 | For |
| BNY Mellon | 66,306 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 65,647 | 0 | 0 | 0 | For |
| Voya | 62,413 | 0 | 0 | 0 | For |
Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,928,760 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 7.80% |
| 2 | Vanguard | 6.76% |
| 3 | Fidelity | 2.93% |
| 4 | State Street | 2.20% |
| 5 | T. Rowe Price | 1.49% |
| 6 | American Century | 1.06% |
| 7 | Charles Schwab | 0.82% |
| 8 | Invesco | 0.63% |
| 9 | JPMorgan | 0.43% |
| 10 | Hartford | 0.32% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RTW INVESTMENTS, LP | 9.18% |
| 2 | FARALLON CAPITAL MANAGEMENT LLC | 7.57% |
| 3 | Deep Track Capital, LP | 5.25% |
| 4 | BVF INC/IL | 4.16% |
| 5 | State Street | 4.09% |
| 6 | BlackRock | 3.19% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.31% |
| 8 | T. Rowe Price | 1.92% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.81% |
| 10 | ADAR1 Capital Management, LLC | 1.36% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with BlackRock, Inc. | 15.96% | DEF14A |
| BlackRock | 15.72% | 13F |
| Entities affiliated with Farallon Partners, L.L.C. | 10.03% | DEF14A |
| Farallon Partners, L.L.C. | 9.89% | 13G |
| Entities affiliated with RTW Investments, L.P. | 8.58% | DEF14A |
| RTW Investments, LP | 8.17% | 13G |
| Vanguard Group | 6.91% | 13F |
| Entities affiliated with The Vanguard Group | 6.81% | DEF14A |
| Vanguard Portfolio Management | 5.70% | 13G |
| Entities affiliated with Deep Track Capital, LP | 5.25% | DEF14A |
Percentages above are of 61,928,760 shares outstanding, as reported by PROTAGONIST THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PROTAGONIST THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 7, 2026; a live search always shows the current data.
At PROTAGONIST THERAPEUTICS INC.'s shareholder meeting held June 20, 2025, in the 2024-2025 proxy season, 303 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,453 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — PROTAGONIST THERAPEUTICS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PROTAGONIST THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 26, 2025.
PROTAGONIST THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.